BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 20, 2003
View Archived Issues
FDA Signs Off On Namenda For Moderate To Severe Alzheimer's
Patients suffering from a seemingly hopeless affliction, and those around them, might gain a glimmer of hope on news of the FDA's approval of Namenda (memantine HCL) for Alzheimer's disease. (BioWorld Today)
Read More
President's Council Questions Biotech's Use 'Beyond Therapy'
Read More
Listeria monocytogenes Bacteria Pick, Choose, Young, Old, Pregnant As Victims Of Low-Virulence Death
Read More
Advancis IPO Raises $60M; Biotech Firms Wait In Wings
Read More
Correction
Read More
Durect Stock Falls 35 Percent On Likely Phase III Trial Delay
Read More
Genelabs Rakes In $27.4M For Prestara, Hepatitis C Programs
Read More
Other News To Note
Read More